Revolution Medicines

102 articles about Revolution Medicines

• Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2

  10/12/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that interim data from the company’s ongoing Phase 1b/2 clinical trial (RMC-4630-02) evaluating the combination of RMC-4630 and cobimetinib (Cotellic ® ) will be reported in an oral presentation in a plenary session at the upcoming EORTC-NCI-AACR 32 nd Sy

• Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

  9/16/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported data demonstrating that its first-in-class KRASG12D(ON) inhibitors induced tumor regressions in a preclinical model of human pancreatic cancer carrying an oncogenic KRASG12D mutation.

• Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 22nd Annual Global Investment Conference.

• Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development ConferenceCompany’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event

  9/8/2020

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in the upcoming 2nd Annual RAS-Targeted Drug Development Conference being held virtually September 14-16, 2020.

• Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

  8/10/2020

  Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors Targeted Combination Strategy Underpins Initiation of New Clinical Trials Evaluating RMC-4630 with KRAS G12C  Inhibitor or Anti-PD-1 Antibody $179.4 Million Follow-On Offering Strengthens Balance Sheet

• Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesUnderwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million

  7/13/2020

  Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of an underwritten public offering of 6,900,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions.

• Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock

  7/9/2020

  Revolution Medicines, Inc. announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions.

• Revolution Medicines Announces Proposed Public Offering of Common Stock

  7/6/2020

  Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common stock.

• Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus

  6/30/2020

  Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus

• Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies

  6/22/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the company's innovative portfolio directed against RAS cancers.

• Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 InhibitorCombination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors

  6/22/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda ® ), an anti-PD-1 antibody. The trial, which is being sponsored and conducted

• 

  BioSpace Movers & Shakers, June 19

  6/19/2020

  Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

• Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

  6/18/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the appointments of Eric T. Schmidt, Ph.D., and Peter Svennilson to its board of directors.

• Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

  6/9/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a Phase 1b clinical trial evaluating the combination of RMC-4630, the company’s investigational SHP2 inhibitor, and AMG 510, Amgen’s investigational KRASG12C inhibitor.

• Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting IICompany to Host R&D Update Conference Call Following AACR Meeting

  5/19/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the company will make four presentations at the upcoming 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. 

• Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress

  5/14/2020

  Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, announced its financial results for the first quarter ended March 31, 2020, and provided an update on its R&D pipeline and other corporate developments.

• Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models

  4/29/2020

  Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug

• Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor ProgramMulti-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630

  3/18/2020

  Revolution Medicines, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,590,090 providing, in part, composition of matter protection for its SHP2 inhibitors, including RMC-4630.  RMC-4630, the company’s investigational SHP2 inhibitor, is a potent and orally bioa

• New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute

  3/9/2020

  Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations

• Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  2/18/2020

  Revolution Medicines, Inc. announced the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares of common stock, at a public offering price of $17.00 per share.